Literature DB >> 23896570

Tipepidine activates VTA dopamine neuron via inhibiting dopamine D₂ receptor-mediated inward rectifying K⁺ current.

R Hamasaki1, T Shirasaki, F Soeda, K Takahama.   

Abstract

We previously reported that the novel antidepressant-like effect of tipepidine may be produced at least partly through the activation of mesolimbic dopamine (DA) neurons via inhibiting G protein-coupled inwardly rectifying potassium (GIRK) channels. In this study, we investigated the action of tipepidine on DA D2 receptor-mediated GIRK currents (IDA(GIRK)) and membrane excitability in DA neurons using the voltage clamp and current clamp modes of the patch-clamp techniques, respectively. DA neurons were acutely dissociated from the ventral tegmental area (VTA) in rats and identified by the presence of the hyperpolarization-activated currents. Tipepidine reversibly inhibited IDA(GIRK) with IC50 7.0 μM and also abolished IDA(GIRK) irreversibly activated in the presence of intracellular GTPγS. Then tipepidine depolarized membrane potential and generated action potentials in the neurons current-clamped. Furthermore, the drug at 40 mg/kg, i.p. increased the number of cells immunopositive both for c-Fos and tyrosine hydroxylase (TH) in the VTA. These results suggest that tipepidine may activate DA neurons in VTA through the inhibition of GIRK channel-activated currents.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT; DA; G protein-coupled inwardly rectifying potassium channel; G-protein-coupled inwardly rectifying potassium; G-protein-coupled receptor; GIRK; GPCR; I(Baclofen); I(DA(GIRK)); I(DA); I(h); IPSCs; NA; NAT; NAc; OCD; PB; S.E.M.; SERT; SNc; TBS; TBST; TH; TritonX-100 in TBS; VTA; acutely dissociated neuron; baclofen-induced current; dopamine; dopamine D(2) receptor-mediated GIRK current; dopamine-induced current; hyperpolarization-activated cation current; inhibitory postsynaptic currents; noradrenaline; noradrenaline transporter; nucleus accumbens; obsessive–compulsive disorder; patch clamp; phosphate buffer; serotonin; serotonin transporter; standard error of the mean; substantia nigra pars compacta; tipepidine; tris-buffered saline; tyrosine hydroxylase; ventral tegmental area

Mesh:

Substances:

Year:  2013        PMID: 23896570     DOI: 10.1016/j.neuroscience.2013.07.044

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Neuronal G protein-gated K+ channels.

Authors:  Haichang Luo; Ezequiel Marron Fernandez de Velasco; Kevin Wickman
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-15       Impact factor: 5.282

2.  Suprachiasmatic nucleus function and circadian entrainment are modulated by G protein-coupled inwardly rectifying (GIRK) channels.

Authors:  L M Hablitz; H E Molzof; J R Paul; R L Johnson; K L Gamble
Journal:  J Physiol       Date:  2014-09-12       Impact factor: 5.182

Review 3.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

Review 4.  Alcohol modulation of G-protein-gated inwardly rectifying potassium channels: from binding to therapeutics.

Authors:  Karthik Bodhinathan; Paul A Slesinger
Journal:  Front Physiol       Date:  2014-02-25       Impact factor: 4.566

5.  Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Takuya Saito; Yushiro Yamashita; Akemi Tomoda; Takashi Okada; Hideo Umeuchi; Saki Iwamori; Satoru Shinoda; Akiko Mizuno-Yasuhira; Hidetoshi Urano; Izumi Nishino; Kazuhiko Saito
Journal:  BMC Psychiatry       Date:  2020-11-10       Impact factor: 3.630

6.  Pathway analysis in attention deficit hyperactivity disorder: An ensemble approach.

Authors:  Michael A Mooney; Shannon K McWeeney; Stephen V Faraone; Anke Hinney; Johannes Hebebrand; Joel T Nigg; Beth Wilmot
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-03-22       Impact factor: 3.568

7.  Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study.

Authors:  Tsuyoshi Sasaki; Kenji Hashimoto; Masumi Tachibana; Tsutomu Kurata; Keiko Okawada; Maki Ishikawa; Hiroshi Kimura; Hideki Komatsu; Masatomo Ishikawa; Tadashi Hasegawa; Akihiro Shiina; Tasuku Hashimoto; Nobuhisa Kanahara; Tetsuya Shiraishi; Masaomi Iyo
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-24       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.